Prostate cancer (urology)

The prostate is a small gland, about the size of a walnut, that sits just below the bladder in men and people assigned male at birth. It surrounds the tube that carries urine out of the body (the urethra) and helps make some of the fluid in semen. Prostate cancer happens when cells in this gland begin to grow and multiply in a way the body cannot control.

It helps to know that prostate cancer is usually not the fast, aggressive disease many people imagine. As Cleveland Clinic puts it, "most prostate cancers grow slowly inside the prostate gland." Many men live for years with prostate cancer that never causes them harm, and some will be advised simply to monitor it rather than treat it straight away.

Prostate cancer is common. The American Cancer Society and other authorities note that roughly 1 in 8 men will be diagnosed with it at some point in life, and the chance rises with age. It mainly affects men over 50, and the median age at diagnosis is around 68 years. Because it is so common and often slow-growing, the goal of care is not to treat every cancer aggressively, but to identify which cancers need action and which can safely be watched.

The great majority of prostate cancers are a type called adenocarcinoma — cancer that starts in the gland cells that make prostate fluid. When people talk about "prostate cancer" in general, this is almost always what they mean.

There are rarer types, including small cell (neuroendocrine) prostate cancer, transitional cell (urothelial) cancer, sarcomas, and others. These behave differently from ordinary adenocarcinoma and are managed by specialists accordingly. Because they are uncommon, most of the information you will read — including this guide — focuses on adenocarcinoma.

Rather than classic "subtypes," what matters most day to day is how a prostate cancer is graded and staged — in other words, how abnormal the cells look under a microscope and how far the cancer has spread. Doctors also group cancers into risk categories (often described as low, intermediate, or high risk) by combining the grade, the stage, and the level of a blood marker called PSA. These groupings, explained later, guide the choice of treatment far more than any single label.

The exact cause of prostate cancer is not fully understood. As with most cancers, it develops when changes (mutations) build up in cells over time, causing them to grow when they should not. You cannot "catch" prostate cancer, and in most cases there is nothing a person did to cause it.

Some factors are known to raise the risk. According to the American Cancer Society and NHS, the main ones are:

• Age. Prostate cancer is rare under 40 and becomes much more likely after 50. About 6 in 10 cases are found in men older than 65.
• Ethnicity. Prostate cancer is more common, and can be more aggressive, in men of Black African or African-Caribbean heritage. It is less common in Asian men.
• Family history. Having a father or brother who had prostate cancer more than doubles a man's risk. The risk is higher when relatives were diagnosed young or when several family members are affected.
• Inherited gene changes. Faults in genes such as BRCA2 (and to a lesser extent BRCA1), and the condition known as Lynch syndrome, can increase risk and may be linked to faster-growing cancers.

Other factors — including diet, body weight, smoking, and certain chemical exposures — have been studied, but the evidence is weaker or mixed. Importantly, having one or more risk factors does not mean you will get prostate cancer, and many men with the disease have no obvious risk factors at all.

One of the most important things to understand is that early prostate cancer often causes no symptoms at all. The NHS states plainly that "prostate cancer often has no symptoms at first." This is because the cancer usually starts in a part of the prostate that does not press on the urethra early on.

When symptoms do appear, they often relate to urination, and may include:

• Difficulty starting to urinate, or having to strain
• A weak flow, or a stop-start flow
• Needing to urinate more often or more urgently, especially at night
• Feeling that the bladder has not fully emptied
• Blood in the urine or semen
• Erectile difficulties (trouble getting or keeping an erection)

Here is the reassuring part: these urinary symptoms are far more often caused by a benign (non-cancerous) enlargement of the prostate, a very common condition as men age, rather than by cancer. Less common symptoms such as ongoing lower back or hip pain and unexplained weight loss can be signs of more advanced disease.

See a doctor if you have any of these symptoms, or if you are over 50, have a Black ethnic background, or have a family history of prostate cancer and want to discuss your risk. As the NHS gently advises, "try not to be embarrassed if you have possible symptoms." A timely conversation is always worthwhile — and most of the time it brings reassurance rather than bad news.

Unlike some cancers, there is no national screening programme for prostate cancer in countries such as the UK. The reason is not neglect — it reflects a genuine difficulty with the main available test.

The PSA test measures a protein called prostate-specific antigen in the blood. A higher level can be a sign of cancer, but it can also rise because of a benign enlarged prostate, infection, or even recent activity. The test cannot tell the difference between a harmless, slow-growing cancer and one that needs treatment. According to Cancer Research UK, roughly 3 in 4 men with a raised PSA turn out not to have cancer, and a normal PSA does not completely rule cancer out. This means PSA testing can lead to anxiety, extra tests, and sometimes treatment of cancers that would never have caused harm — alongside its real ability to catch important cancers earlier.

Because of this balance, the recommended approach is informed, shared decision-making rather than blanket screening. The American Cancer Society suggests men discuss the pros and cons of PSA testing with a clinician at age 50 for average risk, age 45 for higher risk (including Black men and those with a close relative diagnosed before 65), and age 40 for those at the highest risk. The decision is personal, and there is no single right answer — the aim is to choose with your eyes open.

If a PSA result, a physical examination, or symptoms raise a question, the next steps usually unfold in a logical order. A doctor may perform a digital rectal examination (DRE), gently feeling the prostate through the wall of the rectum to check its size and texture. This takes seconds and, while not the most comfortable test, is brief and well tolerated.

Modern pathways often use an MRI scan of the prostate next. The NHS notes that an MRI can give "a clearer view of the prostate and show if you need any more tests." A good-quality MRI can help avoid unnecessary biopsies and can guide the biopsy if one is needed.

The only way to confirm prostate cancer is a biopsy, in which a fine needle takes small tissue samples from the prostate so they can be examined under a microscope. A specialist doctor (a pathologist) then assigns a Gleason score and a Grade Group, which describe how abnormal the cells look and therefore how likely the cancer is to grow and spread. Gleason scores run from 6 to 10; Grade Group 1 (Gleason 6) is the least aggressive and Grade Group 5 (Gleason 9–10) the most.

If cancer is confirmed, staging tests such as CT, MRI, PET, or bone scans may be used to see whether it has spread. Doctors describe the stage from I to IV: stage I cancer is small and confined to the prostate, while stage IV has spread to lymph nodes or distant sites such as bone. Stage, grade, and PSA together shape the treatment plan.

There is rarely a single "correct" treatment for prostate cancer. The right choice depends on the cancer's stage and grade, your age and general health, and your own preferences about possible side effects. Decisions are usually made by a multidisciplinary team — typically a urologist (surgeon), a clinical or radiation oncologist, a pathologist, a radiologist, and specialist nurses — who review your case together.

Broadly, the options are:

• Active surveillance. For low-risk, slow-growing cancer, the team may recommend monitoring with regular PSA tests, examinations, scans, and sometimes repeat biopsies, treating only if the cancer shows signs of progressing. This avoids the side effects of treatment in men who may never need it.
• Watchful waiting. A lighter form of monitoring, often used in older men or those with other health conditions, focusing on managing symptoms if and when they appear.
• Surgery (radical prostatectomy). Removal of the whole prostate gland, often using keyhole or robot-assisted techniques. The NHS notes possible side effects including urinary leakage and erectile difficulties, which often improve over months.
• Radiotherapy. High-energy radiation given from outside the body (external beam) or from radioactive seeds placed inside the prostate (brachytherapy). It is used for cancer confined to or near the prostate, and sometimes to control symptoms in advanced disease.
• Hormone therapy. Because testosterone fuels prostate cancer, injections or tablets that lower or block it can slow the cancer. The NHS is clear that hormone therapy "does not cure prostate cancer, but it can slow it down," and it is often combined with radiotherapy or used in advanced disease.
• Chemotherapy and newer drugs. For more advanced or spreading cancer, options include chemotherapy, targeted drugs (such as PARP inhibitors for certain gene faults), and immunotherapy in selected cases.

Supportive care — managing urinary, sexual, and bowel side effects, bone health, and emotional wellbeing — is an important part of treatment at every stage.

For many men, the outlook with prostate cancer is genuinely encouraging, particularly when it is caught before it spreads. Survival figures are best understood as population-level statistics: they describe large groups of people, and they cannot predict what will happen to any one individual.

Using United States SEER data, the overall five-year relative survival for prostate cancer is about 98%. When the cancer is found while still localised (confined to the prostate) or has spread only to nearby tissue, five-year relative survival approaches 100%. When the cancer has spread to distant parts of the body, that figure is around 40%.

It is important to read these numbers carefully and kindly. As the SEER source itself cautions, "because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly." Survival figures also reflect outcomes from years ago and do not capture the newest treatments. Your own specialist, who knows the full details of your case, is the only person who can discuss what these statistics mean for you.

Whether you are on active surveillance or have completed treatment, prostate cancer care usually continues with regular follow-up. This typically includes periodic PSA blood tests and check-ups, which help your team spot any change early and step in if needed. Knowing there is a clear monitoring plan can be reassuring in itself.

Some treatments have side effects that take time to settle. Urinary leakage after surgery often improves over the first 6 to 12 months, and pelvic floor exercises can help. Erectile difficulties are common but can often be managed with medication (such as sildenafil or tadalafil) or other approaches; your team can advise on what suits you. If preserving fertility matters to you, ask about sperm banking before treatment starts, as some treatments affect fertility.

The emotional side matters too. A cancer diagnosis can bring anxiety, low mood, or strain on relationships, and that is entirely normal. Specialist nurses, counsellors, and patient support groups can make a real difference. Eating well, staying physically active within your ability, limiting alcohol, and not smoking all support your general health and recovery. Do not hesitate to raise concerns — about symptoms, side effects, or feelings — with your care team; they expect and welcome these conversations.

If you are considering treatment in another country, it helps to understand what shapes the overall cost so you can plan realistically. We do not list prices here, because the right figure depends entirely on your individual situation and is best given as a personalised estimate after your records are reviewed.

The main factors that influence cost include:

• The type of treatment chosen — for example, robot-assisted surgery, external radiotherapy, brachytherapy, hormone therapy, or a combination.
• The stage and grade of the cancer, which determine how complex and how long treatment needs to be.
• The diagnostic work-up required, such as MRI, biopsy, and staging scans, and whether recent results can be reused.
• The length of hospital stay and recovery, follow-up appointments, and any supportive care or medication.
• Practical costs such as travel, accommodation, interpreting, and an accompanying companion.

To get an accurate estimate, gather your medical records in advance: PSA results over time, the biopsy and pathology report (including Gleason score and Grade Group), any MRI or scan images and reports, a summary of your medical history and current medicines, and contact details for your current doctor. Clear, complete records let a specialist team plan precisely and avoid repeating tests. A free consultation is the simplest way to have your records reviewed and receive a tailored, no-obligation estimate.

Turkiye has become a well-established destination for medical care, with hospitals that treat large numbers of international patients and offer modern urological and oncology services, including robot-assisted surgery and advanced radiotherapy. For many people, the appeal is the combination of experienced specialist teams and the convenience of organised, all-in-one care.

What matters far more than any destination, however, is choosing a centre carefully and on the right criteria. Sensible things to verify include:

• Accreditation. Look for recognised quality accreditation, such as Joint Commission International (JCI), and a hospital with a dedicated oncology and urology department.
• The specialist team. Confirm that a true multidisciplinary team will review your case, and ask about the experience of the urologist and oncologist with prostate cancer specifically.
• Technology and approach. Ask which treatment techniques are available and which is recommended for your situation, and why.
• Clear, written information. A reputable centre will explain the plan, the likely side effects, the follow-up arrangements, and the costs transparently, in a language you understand.
• Continuity of care. Ask how follow-up and any complications will be handled after you return home, and how results will be shared with your local doctor.

Be cautious of anyone who promises a guaranteed cure or uses pressure to make you decide quickly. Good care is never rushed, and a trustworthy team will encourage you to ask questions and, if you wish, to seek a second opinion.

Because prostate cancer is so widely studied, there is a steady stream of research into new treatments and ways to reduce side effects. Clinical trials are carefully regulated studies that test promising approaches, and for some patients they offer access to options not yet in routine use. Trials are entirely voluntary, you can withdraw at any time, and your team can tell you whether any are suitable for you. Reputable information on trials is available through national cancer organisations such as the National Cancer Institute.

Seeking a second opinion is a normal and reasonable step, not a sign of distrust. Prostate cancer often involves genuine choices — for example, surveillance versus immediate treatment, or surgery versus radiotherapy — where reasonable specialists may weigh things differently. Hearing the question explained by more than one expert can help you feel confident in the path you choose. Most doctors fully expect and support this.

Finally, there is no single proven way to prevent prostate cancer, but a generally healthy lifestyle — a balanced diet, regular activity, a healthy weight, not smoking, and moderate alcohol — supports your overall wellbeing. If you have a strong family history or a known gene fault such as BRCA2, ask your doctor whether earlier conversations about PSA testing or genetic counselling would be wise for you.